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Abstract: Obesity, a recognized risk factor for breast cancer in postmenopausal women, is associated
with higher mortality rates regardless of menopausal status, which could in part be explained by
therapeutic escape. Indeed, adipose microenvironment has been described to influence the efficiency
of chemo- and hormonal therapies. Residual cancer stem cells could also have a key role in this
process. To understand the mechanisms involved in the reduced efficacy of hormonal therapy on
breast cancer cells in the presence of adipose secretome, human adipose stem cells (hMAD cell
line) differentiated into mature adipocytes were co-cultured with mammary breast cancer cells and
treated with hormonal therapies (tamoxifen, fulvestrant). Proliferation and apoptosis were measured
(fluorescence test, impedancemetry, cytometry) and the gene expression profile was evaluated. Cancer
stem cells were isolated from mammospheres made from MCF-7. The impact of chemo- and hormonal
therapies and leptin was evaluated in this population. hMAD-differentiated mature adipocytes
and their secretions were able to increase mammary cancer cell proliferation and to suppress the
antiproliferative effect of tamoxifen, confirming previous data and validating our model. Apoptosis
and cell cycle did not seem to be involved in this process. The evaluation of gene expression profiles
suggested that STAT3 could be a possible target. On the contrary, leptin did not seem to be involved.
The study of isolated cancer stem cells revealed that their proliferation was stimulated in the presence
of anticancer therapies (tamoxifen, fulvestrant, doxorubicine) and leptin. Our study confirmed the
role of adipocytes and their secretome, but above all, the role of communication between adipose and
cancer cells in interfering with the efficiency of hormonal therapy. Among the pathophysiological
mechanisms involved, leptin does not seem to interfere with the estrogenic pathway but seems to
promote the proliferation of cancer stem cells.
Keywords: breast cancer; adipose secretome; leptin; hormonal therapy resistance; cancer stem cells
1. Introduction
Breast cancer is the most common cancer among women with 523,000 new cases, which represents
13.4% of all cancer cases in Europe and is the leading cause of death in women (138,000, 16.2%) [1].
Many epidemiological studies have confirmed the link between obesity and the development of
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cancers such as colon, prostate, and more recently, ovarian cancer. Overweight and obesity are
associated with a higher risk of postmenopausal breast cancer (RR = 1.12, 95% confidence interval
[95% CI] = 1.09–1.15) [1], larger tumor, positive lymph-node status, and reduced outcome regardless of
menopausal status [2]. Furthermore, weight change during cancer treatment could also be associated
with a poorer diagnosis [3]. Despite the accumulation of evidence linking obesity to the development
of breast cancer, this factor is rarely taken into account and could be decisive in the implementation of
individualized treatment for overweight patients.
The mechanisms by which obesity could interact with the development of cancer are complex and
not fully understood. The importance of the mammary tumor microenvironment in the development,
growth, and progression of cancer is widely recognized today. Interactions between the different
cell types present in the adipose microenvironment are now described. This mammary adipose
microenvironment is very heterogeneous and mainly consists of adipocytes (50% to 80% of the vascular
fraction) as well as a set of cell types forming the stromal-vascular fraction and containing adipose stem
cells, endothelial and immune cells, fibroblasts, as well as extracellular matrix (laminin, fibronectin,
collagens, proteoglycans). Adipose tissue is now considered to be an endocrine organ capable of
secreting soluble factors that can act on surrounding cells and on the composition of the extracellular
matrix [4]. These are mainly growth factors, cytokines, adipokines, proteases, or vascular stimulation
factors. Breast stroma can undergo phenotypic and functional changes to be active and provide a
favorable environment for mammary tumor development [5].
Resistance of cancer cells to therapies has been proposed to explain the link between obesity and
the higher mortality observed in breast cancer patients. Indeed, studies suggest such resistance for
aromatase inhibitors [6] or neoadjuvant chemotherapies, such as anthracyclines and taxanes [7]. About
70% of breast cancers express estrogen receptors (ER+) and the most effective treatment is hormonal
therapy which blocks estrogen activity. Current hormonal therapies are mainly tamoxifen (Tx), an
estrogen receptor antagonist, fulvestrant (Fv), a pure anti-estrogen responsible for the downregulation
and degradation of this receptor, and aromatase inhibitors such as anastrozole and letrozole [8].
Unfortunately, de novo or acquired resistance could be developed, leading to disease progression and
increased mortality, which could be amplified in overweight women [9]. Some authors demonstrated
that aromatase inhibitors may be less efficient than tamoxifen in overweight and obese patients [10].
Tx resistance seems to be multifactorial with, for example, the lack of ER function or disruption of
signaling pathways (RTK, PI3K, NF-kB) [11].
The role of cancer stem cells (CSCs) in hormonal therapy resistance has also been investigated.
CSCs have common properties with normal stem cells, including their ability to self-renew and
differentiate [12], but also additional specific features, such as uncontrolled proliferation and partial or
abnormal differentiation, contributing to increased tumorigenicity in component tumors, potentially
driving metastases. CSCs, previously discovered in liquid tumors, were finally found in solid tumors
such as breast cancer in which CSCs could represent 0.1% to 2% of all breast cancer cells [13]. Breast
CSCs express a particular phenotype based on the expression of markers such as CD44+/CD24−,
an enzymatic activity of aldehyde dehydrogenase (ALDH), an overexpression of transmembrane
pumps (ATP-binding cassette, subfamily G, member 2 ABCG2) leading to the exclusion of Hoechst
33342 fluorescent probe and the characterization of a cell population called a “side-population” (SP)
fraction [14]. These SP fraction may therefore be able to reject toxic drugs, indicating their involvement
in cancer drug resistance. The role of CSCs in resistance to hormonal therapy has also been investigated.
Tx is able to promote the CSCs survival in MCF-7, since a pretreatment with 4-hydroxytamoxifen
(4-OH-Tx), a metabolite of Tx, raises their ability to form mammospheres [15].
Thus, a worse prognosis is observed in obese or overweight women treated with hormone therapy
with Tx that is more effective than anti-aromatase inhibitors, the resistance mechanisms remaining
unknown. So the aim of this study was to investigate (i) how obesity could interfere with hormonal
therapies by evaluating the role of the adipose microenvironment in signaling pathways and (ii) the
comportment of isolated mammary CSCs in the presence of hormonal therapy and adipokines.
Nutrients 2019, 11, 2839 3 of 16
2. Materials and Methods
2.1. Study of Breast Cancer Cells
2.1.1. Cell Culture
Breast cancer cells. MCF-7 (estrogen-receptor positive [ER+]) and MDA-MB-231 (ER-) breast cancer
cell lines were obtained from ATCC (Manassas, VA, USA). MCF-7 were cultured in RPMI1640 (Gibco,
Thermo Fisher Scientific, Waltham, MA, USA) supplemented with insulin (0.04 UI/mL) (Sigma-Aldrich,
Saint-Louis, MO, USA), fetal bovine serum (10%), L-glutamine (1%), and gentamycin (50 µg/mL)
(Thermo Fisher Scientific). MDA-MB- 231 were grown in L15 (Thermo Fisher Scientific) supplemented
with FBS (15%), L-glutamine (1%), and gentamycin (50 µg/mL). Cells were incubated at 37 ◦C following
recommendations of ATCC in a humidified 95% air/5% CO2 environment for MCF-7 and 100% air
for MDA-MB-231.
Adipose cells. The human multipotent adipose (hMAD) cell line is a generous gift from C. Dumontet
(University Lyon 1, Lyon, France; INSERM U1052, CNRS 5286, Cancer Research Center of Lyon, Lyon,
France). hMAD were differentiated into mature adipocytes (MA) [16]. For that, adipose cells were
seeded at confluence (33,500 cells/cm2) in a differentiation medium which consisted of DMEM/F12 (1:1)
supplemented with 10% FBS, hydrocortisone, insulin, adenine, EGF, T3, vitamin C, dexamethazon,
roziglitazone, IBMX (only the first three days), gentamycin. The medium was replaced every two days.
MA were obtained after 12 days of differentiation.
All the cells were under mycoplasma-free conditions (MycoAlertTM PLUS Mycoplasma detection
Kit, Lonza, Basel, Switzerland).
2.1.2. Influence of Adipose Secretome
To assess the specific role of adipose secretome, the proliferation of mammary cancer cells (MCF-7
and MDA-MB-231) cultured with conditioned media (CM) obtained from the culture of the MA was
evaluated using the iCELLigence technology which allows automatic monitoring of cell adherence and
proliferation in real-time. CM were collected after 48 h of culture of MA in DMEM/F12 supplemented
with FBS (10%) and glutamine (1%). Before use, they were kept under nitrogen atmosphere at −80 ◦C.
After 24 h of adhesion in the iCELLigence system, cells were exposed to CM (dilution 1:1 in fresh
complete adipose cell media) and/or tamoxifen (Tx, IC50 = 10 µM, Sigma-Aldrich) for 72 h. The
impedance value of each well was measured by the iCELLigence system every 10 min for 72 h and
expressed as cell index (CI) values. Data for cell adherence were normalized at 24 h corresponding to
the time of treatment to give a normalized cell index. Three independent experiments were conducted.
2.1.3. Evaluation of Cell Cell Interactions
A system of co-cultures was used between breast cancer cells seeded at the bottom of wells and
MA seeded in inserts, allowing to assess the interactions between the two cell types through a porous
membrane (Transwell culture system, porosity 0.4µm).
For that, hMAD were seeded in inserts (Merck Millipore, Molsheim, France) and differentiated
into MA for 12 days. At the end of the differentiation, MCF-7 or MDA-MB-231 were seeded
(15,150 cells/cm2) at the bottom of the plate in DMEM/F12 medium supplemented with FBS (10%) and
glutamine (1%). Twenty-four hours later, treatment with antiestrogen (Tx, IC50 = 10µM, or Fv, IC50 =
0.5nM, Sigma-Aldrich) and/or an anti-leptin antibody (0.5 µg/mL) (R&D Systems Europe, Lille, France)
were added in the co-culture system.
The proliferation was measured after 72 h with the resazurin test (3 independent experiments)
(Exw = 530 nm and Emw = 590 nm, Fluoroskan Ascent FL®, Thermo Fisher Scientific). Results were
expressed as a percentage of cell growth ± ESM.
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2.1.4. Annexin V–FITC/PI Apoptosis Assay
MCF-7 mammary cancer cells cultured with CM and/or Tx (10 µM) for 72 h were washed with
phosphate buffered saline (PBS), recovered by centrifugation at 1000 g for 5 min at room temperature
(RT), and suspended in 40 µL of annexin V binding buffer (140 mM NaCl, 10 mM HEPES/NaOH,
2.5 mM CaCl2). The cell suspension was stained with 5 µL of annexin V-FITC and 5 µL of propidium
iodide (PI), and incubated for 15 min at RT in the dark. After the addition of PBS and a centrifugation
at 1000 g for 5 min at RT, cells were suspended in 50 µL of annexin V binding buffer. Stained cells were
then analyzed on a Cellometer K2 image cytometer (Nexcelom Bioscience, Lawrence, MA, USA). Data
were expressed as a percentage of live cells, % of cells in early or late apoptosis and % of necrotic cells.
Experiments were realized three times.
2.1.5. Quantitative Real-Time PCR (qPCR) Assays
Total RNA was extracted from MCF-7 mammary cells that had been co-cultured with MA and
treated with Tx using Trizol (Invitrogen, Thermo Fisher Scientific). After the evaluation of the quantity
and purity (NanoDrop 2000, Thermo Fisher Scientific), DNase treatment (DNase I Amplification grade,
Invitrogen, Thermo Fisher Scientific) and cDNAs retrotranscription (HighCap cDNA RT Kit RNAse
inhib, Invitrogen) were made according to the manufacturer’s recommendations. qPCR was performed
on plates designed by Applied Biosystems (TaqMan® Array 96 well Fast Plate, Custom format 32)
using SDS7900HT automaton (Applied Biosystems, Thermo Fisher Scientific) with TaqMAN® (Applied
Biosystems, Thermo Fisher Scientific). The analysis was conducted on 32 genes (LEPR; LEP; ADIPOQ;
ADIPOR1; ADIPOR2; ESR1; ESR2; PGR; CYP19; CDH1; MMP2; MMP9; IL6; TNF; IGF1; VEGFA; MYC;
AKT1; PTEN; CTNNB1; TWIST1; BAX; BCL2; CCND1; MAPK1; MAPK3; MAPK8; TP53; STAT3) and 3
reference genes (18S; UBC; ACTB). Genes were considered significantly expressed and their transcript
measurable if their corresponding Ct value was less than 35. The relative quantification method (RQ
= 2−∆∆CT) was used to calculate the relative gene expression of given samples with ∆∆CT = [∆CT
(sample1) − ∆CT (sample2)] and ∆CT = [CT (target gene) − geometric mean CT (reference genes)].
Paired t-tests were used to compare gene expression levels with at least 2 valid pairs of values. Control
of the false discovery rate due to multiple testing was done according to the Benjamini Hochberg
method for each comparison separately. Using ∆CT values, gene expression was plotted as a heatmap,
paired with a two-way hierarchical cluster analysis (package “gplots”) in R version 3.5.0. To infer how
gene expression covaried with the factors “Tx treatment” and “co-cultured MCF-7”, a multiple factor
analysis (MFA) was carried out on ∆CT using the package “FactoMineR”.
2.2. Study of Cancer Stem Cells (CSCs)
2.2.1. Mammosphere Formation
MCF-7 cells were seeded (8 × 103 cells) in 96 wells in “Ultra Low Attachment Plates” (Corning,
NY, USA) in DMEM/F12 without phenol red (Gibco, Thermo Fisher Scientific) supplemented with
b-FGF (10 ng/mL; Merck Millipore, Darmstandt, Germany), EGF (20 ng/mL; Gibco), B27 (2%; Gibco),
and gentamicin (50 mg/mL), in a 5% CO2-humidified incubator at 37 ◦C. After 7 days of culture,
mammospheres were recovered by gentle pipetting, dissociated in accutase (Merck Millipore) for
30 min at 37 ◦C, reseeded and cultured in the same conditions until passage 3.
2.2.2. Staining of Side-Population Cells (SP) by Flow Cytometry
SP staining was essentially performed as described by Goodell et al. [17]. Single cell suspensions
of parental MCF-7 or mammospheres (106 cells/mL), obtained after incubation in accutase (30 min),
were incubated in DMEM/F12 (2% FBS, 5 mg/mL Hoechst 33342, 120 min, 37◦; Sigma-Aldrich) in
a dark water bath under agitation with or without ABC transporter inhibitor (50 µM Verapamil,
Sigma-Aldrich). After incubation, cells were maintained at 4 ◦C to inhibit dye eﬄux.
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2.2.3. Phenotyping of SP Cells
Cells were incubated in cold PBS-2% FBS with directly-conjugated primary antibodies or isotype
controls, i.e., CD44 FITC (10 µL per test) or CD24 PE (10 µL per test) (BD Pharmingen, San Jose, CA,
USA) for 20 min at 4 ◦C in the dark according to the manufacturer’s instructions. PI (5 µg/mL) was
added to discriminate dead cells, and cell suspensions were filtered through a 40 µm cell strainer (BD
Biosciences, San Jose, CA, USA) just prior to analysis.
2.2.4. Identification of ALDH-1-Expressing Cells
Cells were analyzed using an ALDEFLUOR detection kit (StemCell Technologies, Vancouver, BC,
Canada) according to the manufacturer’s instructions. The activated BODIPYTM-aminoacetaldehyde
(BAAA) is a fluorescent non-toxic substrate for ALDH that diffuses into viable cells. In the presence
of ALDH1, BAAA is converted into BODIPYTM-minoacetate, which is retained inside the cells. The
amount of fluorescence reaction is proportional to ALDH1 activity. A specific inhibitor of ALDH,
diethylaminobenzaldehyde (DEAB), is used to control for background fluorescence.
2.2.5. Cytometry Analysis, Cell Sorting
Viable cells were analyzed and isolated by flow cytometry (BD FACSAria SORP, BD Biosciences)
using an 85 µm nozzle. Data was acquired at 4 ◦C using BD Diva 7.0 software. The cytometer was
equipped with an UV laser (OPSL 3.6, 100 mW, Coherent). Hoechst Blue and Hoechst Red were
detected on a linear scale with a filter combination consisting of a 450/50-nm bandpass filter (Blue), a
670/30-nm bandpass filter (Red), and a 600-nm longpass filter to split the emission wavelengths. PI
emission was measured on a logarithmic scale using a 695/40-nm bandpass filter and 488-nm excitation.
2.2.6. Proliferation
Isolated SP cells were seeded (5 × 103 cells) in 96-well plates in RPMI 1640 without phenol red
supplemented with FBS 10%, L-glutamine (2 mM), and gentamicin (50 mg/mL). After 24 h, the medium
was replaced and cells were treated with Tx (7.5 and 12.5 µM), doxorubicine (Doxo, 0.1 µM), Fv
(0.3 nM), leptin (1000 ng/mL) (R&D systems, Abingdon, UK). Cell proliferation was measured by a
resazurin fluorescence test (25 µg/mL) at 24 h post-incubation as described previously. Results were
expressed in arbitrary units of fluorescence.
2.3. Statistics
Results were expressed as mean +/− SEM. Statistical analysis was performed using the paired,
bilateral Student’s t-test, or three-way ANOVA with RStudio, regression with Fisher’s PLSD Post-Hoc
test PLSD with StatView® Software (SAS Institute Inc., Cary, NC, USA).
3. Results
3.1. Study of Breast Cancer Cells
3.1.1. Crosstalk between Mammary Cancer Cells and Adipocytes Is a Key Element in the Resistance of
Antiestrogen Therapy and Can Be Mediated by the Indirect Estrogen Pathway
In the presence of Tx (a selective estrogen receptor modulator (SERM), the proliferation of MCF-7
breast cancer cells was reduced (−50%) (Figure 1A,B), corresponding to expected results since the
half-maximal inhibitory concentration was used (IC50 = 10 µM) as in our previous experiments [18].
When cancer cells were exposed to adipose secretome through the use of CM (Figure 1A), MCF-7
proliferation was slightly increased (+130%, ns). The antiproliferative effect of Tx was reduced but not
significantly (−25% in the presence of CM and Tx vs. −50% with Tx only, ns).
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72 h post-treatment (n = 3, * p < 0.05, ** p < 0.01). [CM: conditioned medium; MA: mature adipocytes]. 
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MB-231, which are ER-mammary cancer cells, with hMAD differentiated cells. Tx was able to 
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presence of mature adipocytes. On the contrary, fulvestrant had no effect on this cell line (Figure 2B). 
Figure 1. Percentage of MCF-7 cell proliferation when (A) cells were cultured with conditioned media
(CM) obtained from the culture of human mature adipocytes (MA) and tamoxifen (Tx); (B) cells were
co-cultured with MA and Tx; (C) cells were co-cultured with MA and fulvestrant. (D) Representative
graph from iCELLigence system. Results are expressed as percentage of MCF-7 cell growth ± SEM at
72 h post-treatment (n = 3, * p < 0.05, ** p < 0.01). [CM: conditioned medium; MA: mature adipocytes].
Co-culture experiments were then realized in order to evaluate the interactions between cancer
and adipose cells in the presence of antiestrogens (Figure 1B). We found that MA and their secretions
were able to double MCF-7 proliferation (+200%, p < 0.05 vs. control), to completely abolish the
antiproliferative effect of Tx and even to increase the MCF-7 proliferation in the presence of Tx (+254%,
p < 0.01 vs. control).
These experim nts confirmed the role of adipocytes and their secretome, but above all, the
crosstalk between adipose and cancer cells.
Similar results were found (Figure 1C) using another antiestrogen agent such as fulvestrant (Fv), a
selective estrogen receptor degrader (SERD). The antiproliferative effect of Fv was completely reversed
in the presence of adipocytes and their secretions. The proliferation was even increased (+200%,
p < 0.05) suggesting that adipocytes could also interfere with this pur antiestrogen.
Since our results suggested that adipocyte and their secretions could modify the antiproliferative
activity of two distinct antiestrogens routinely used in breast cancer treatment, we co-cultured
MDA-MB-231, which are ER-mammary cancer cells, with hMAD differentiated cells. Tx was able to
decrease the proliferation of these ER-cancer cells (Figure 2A) and this effect was reduced in the presence
of mature adipocytes. On the contrary, fulvestrant had no effect on this cell line (Figure 2B). These data
suggested that the reduced antiproliferative effect of Tx observed in the presence of adipocytes was
mediated by another pathway than the direct estrogen receptor pathway.
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Figure 2. Percentage of MDA-MB-231 cell proliferation when co-cultured with mature adipocytes (MA)
in the presence of tamoxifen (A) and fulvestrant (B) (n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001).
Both co-culture and Tx treat ent are responsible for specific gene expression profile.
ultiple factor analysis (MFA) was conducted in order to evaluate the balance between
two qualitative variable (“co-culture” and “Tx treatment” conditions) and quantitative variables
corresponding to gene expression data.
The F analysis revealed the ost po erful di ension ith the condition “Tx treat ent”
( i ension 1 explained 51.37 of the variability). The second di ension corresponding to the
condition “ o-culture” explained 37.75 of the variability (Figure 3 ). Four distinct groups ere
clearly segregated: control cells; co-cultured cells; cells treated ith Tx; co-cultured cells treated ith
Tx. Barycentres of “Tx treated cells”; and “non treated cells” sho ed that Tx treat ent accentuated
the differences bet een groups according to dimension 1 (green lines). Similarly, barycenters of
“co-cultured cells” and “non treated cells” showed that the co-culture accentuated the differences
bet een groups according to di ension 2 (red lines). Blue lines corresponded to the influence of gene
expression. n analysis ith circle correlation as ade (Figure 2B) and a resu e of the F is
supplied in Figure 3C. ierarchical cluster analysis (Figure 3 ) segregated cell types according to Tx
treat ent hich had a high i pact on gene expression.
Apoptosis and cell cycle would not be the biological pathways involved in Tx resistance in
our experiments.
The analysis with circle correlation (Figure 3B) permitted to observe that Tx treatment was
positively correlated with the expression of MYC and negatively with BCL2, AKT1, CCND1. Gene
expression analysis (Figure 4) showed that the expression of BCL2, which was increased in co-cultured
MCF-7, was greatly reduced in the presence of Tx (co-cultured MCF-7: relative expression [RE] =
1.48, p < 0.05; co-cultured MCF-7 + Tx: RE = 0.49, p < 0.05). The expression of Bax was not modified
between conditions. Akt and CCND1 (cyclin D1) were under-expressed in the presence of Tx (AKT: RE
= 0.68, p = 0.16; CCND1: RE = 0.35, p < 0.05) and their expression remained stable when cells where
cultured with mature adipocytes.
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Ta g t in Tx R sistanc in the Presence of an dipose icroenviron ent
dip i d t str p t w ,
the condit on “Tx treatment” was positively correlated with the expression ofTNF and the co ition
“co-culture” was positively correlat d with the expression of STAT3 and E R2. The evaluation of
gene expression (Figure 4) revealed that ESR1 w s significantly under-expressed duri g Tx expo ure,
and that this expression returned to a level comparable to that of control in the presence of adipos
cells. qPCR analyses also showed a significant increase of STAT3 expression in the presence of adipose
secretome and Tx, suggesting that this pathway may be a target in the drug resistance observed.
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3.1.3. Leptin Does Not Seem to Be Involved in the Reduction of the Antiproliferative Effect
of Tamoxifen
We then investigated if leptin, a major adipokine whose concentrations are increased in obese
people, could be involved in the resistance to hormonal therapy. An anti-leptin antibody was used
at a concentration of 0.5 µg/mL (according to supplier’s recommendations), which is the highest
concentration that we have found in the media, thus neutralizing all the leptin present in our
experiments ([leptin] = 3.1 ng/mL in CM). When MCF-7 mammary cancer cells were co-cultured
with adipocytes, the anti-leptin antibody had no effect (Figure 6) suggesting that leptin was not the
adipokine involved in the decreased antiproliferative effect of Tx. The ANOVA only revealed the
discrimination between co-cultured cells vs. non-cultured cells. The analysis of gene expression did
not indicate the involvement of leptin, adiponectin, and their receptors in the lower efficiency of Tx.
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tamoxifen and anti-leptin antibody (Percentage of growth ± SEM, n = 3, * p < 0.05, ** p < 0.01).
nticancer Treat ent and dipokines Increase the Proliferation of Isolated SP Cells
The identification of L 1+ cells (Figure 7) permitted us to identify 0.1% of ALDH1+ CSCs
in parental MCF-7. This number was obtained by subtracting the percentage of ALDH1+ (DEAB+)
cells from the percentage of ALDH1+ (DEAB-). When a mospheres were formed after 3 eeks of
culture, the nu ber of L 1+ cells as doubled in the cell population.
CD24low/CD44+ fraction was similarly increased in mammospheres in comparison with parental
MCF-7 cells (from 1.3% in parental MCF-7 cells (Figure 8A) to 3% in mammospheres (Figure 8B)). SP
fraction was similarly increased in mammospheres, compared to parental MCF-7 cells (0.5% in parental
MCF-7 cells (Figure 8C) to 3% (Figure 8D)). In both MCF-7 (Figure 8E) or mammosphere culture
(Figure 8F) conditions, the ABC transporter inhibitor (Verapamil) was able to inhibit Hoechst exclusion,
resulting in the disappearance of SP cells in the gate and thus confirming the proper identification of
SP cells.
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Figure 8. Characterization of the expression of CD24low/CD44+ and the side-population (SP) cells in
parental MCF-7 cells and mammospheres. To determine CD24low/CD44+ expression in (A) MCF-7
cells and (B) mammospheres, cells were incubated with anti-CD24 (PE) and anti-CD44 (FITC) or isotype
controls. The SP cells were analyzed without ABC transporter inhibitor Verapamil in (C) MCF-7 cells
and (D) mammospheres, or with 50 µM of Verapamil in (E) MCF-7 and (F) mammospheres by Hoechst
33342 staining and flow cytometry.
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The impact of isolated CSCs in anticancer therapy resistance and the influence of adipokines were
evaluated on isolated SP cells after exposure to Tx, Fv, Doxo, or leptin. Cell proliferation was measured
at 24 h by resazurin assay (Figure 9). All the anticancer molecules used have shown an increase in
the SP cell proliferation after 24 h of treatment. In the same way, the SP cell proliferation was also
significantly increased after leptin treatment.
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experiments; * p < 0.05, ** p < 0.01, treated vs. control.
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JAK/STAT pathway could be involved. In the literature, Janus kinases (JAK) and signal transduction
and transcription activation (STAT) proteins, particularly STAT3, are described as the most promising
targets for cancer treatment. STAT3 is described as both a transcriptional activator and an oncogene
that is tightly regulated under physiological conditions. STAT3 is constitutively activated in all breast
cancer subtypes and predominantly in triple-negative cancers [25]. A large number of molecules
are able to activate the STAT3 pathway. Firstly, cytokines (IL-6, IL-8, IL-11, Oncostatin, IL-10, IL-32),
and growth factors are able to bind to receptors with tyrosine kinase activity (RTK) such as EGFR,
HER, VEGFR, but also non-RTK (Src) receptors. The activation of STAT3 results in the activation of
cell proliferation, survival, invasion, angiogenesis, and also in the epithelial-mesenchymal transition
(EMT) [25,26]. Recently, authors highlighted the role of IL-6 in therapeutic resistance [27] and in
inducing an EMT-phenotype. By deactivating the secretion of IL-6 by adipocytes and cancer cells, they
managed to decrease proliferation, migration, invasion, and EMT, suggesting the paracrine role of this
adipokine [28]. Thus, the different actors of the mammary adipose microenvironment and the cancer
cells themselves can activate the STAT3 pathway in an autocrine or paracrine manner.
A large proteomic study of adipose tissue samples collected next to mammary tumors identify a
large number of hormones, cytokines, and growth factors involved in various biological pathways such
as signal transduction, cell growth, immune response, or apoptosis [29]. Recently, conditioned media
of mammary adipose tissue from women with breast cancer have been shown to promote proliferation,
adhesion, and migration of mammary epithelial cells, contrary to the conditioned media from the
adipose tissue of non-cancer patients, suggesting the importance of soluble adipose tissue factors
nearby tumor cells [30]. In addition, mammary cancer cells may alter the phenotype of adipocytes,
which in turn would promote tumor aggressiveness and local invasion [31]. These adipocytes located
near the tumor are called “cancer-associated adipocytes” (CAA) and are characterized by a loss of lipid
content, a decrease in late marker expression of adipogenesis, and an overexpression of inflammation
markers (IL-6, IL-1β) and proteases (MMP-11, PAI-1) [31]. A recent study confirmed that CAA are
smaller than adipocytes located more than 2 cm from the tumor or adipocytes from a breast without
tumor. Moreover, it seems that these adipocytes more strongly express the versican (proteoglycan
involved in the binding of cells with the extracellular matrix), AdipoR1 (compensatory phenomenon
following the decrease of the expression of adiponectin), and CD44 (role in the adhesion and migration),
and on the contrary show a decrease in the expression of adiponectin and perilipin (MA marker) [32].
We had previously shown the role of leptin in interfering with anti-cancer treatments [23], and
herein we wanted to see if leptin had any activity on cancer stem cells (CSCs). Indeed, there is emerging
evidence that CSCs are involved in breast cancerogenesis and resistance to anticancer therapies in
breast cancer. However, the low number of these cells makes their analyses and functionality difficult to
study. Under these conditions, mammosphere formation increased the percentage of SP cells, ALDH1+,
and CD24low/CD44+ fractions and offered a better way to determine the functionality of these cells.
Our results on the treatment of isolated SP fractions showed that CSCs were resistant to anticancer
treatment such as Tx, Fv, and doxorubicin. It was recently found that Tx had the ability to promote the
survival of cells with stem cell properties in MCF-7 cells, since a pretreatment with 4-OH-Tx raised
the ability of these cells to form mammospheres [15]. Conversely, Ao et al. showed that treatment
with 4-OH-Tx or Fv induced a decrease in cell proliferation, even if 4-OH-Tx or Fv did not affect the
ability of these cells to form mammospheres or their tumorigenicity [15]. The difference between the
two studies was explained by the differences in concentrations of 4-OH-Tx used and also in technical
design. Our results also indicated that leptin was able to increase SP cell proliferation. It was previously
shown that leptin was involved in the stimulation and maintenance of breast CSCs [33] and that CSCs
survival, evaluated through mammosphere formation, increased in response to leptin, along with an
increase in leptin receptor gene expression [34]. Adipokines such as leptin could therefore be involved
in CSCs-induced resistance to anti-cancer treatment, especially in overweight patients.
Thus, adipose secretome and cellular interactions seem to play a key role in resistance to hormonal
therapy. This resistance cannot be explained by a single process. Among the pathophysiological
Nutrients 2019, 11, 2839 14 of 16
mechanisms involved, leptin does not seem to interfere with the estrogenic pathway but could favor the
proliferation of CSCs. Further studies are needed to identify targets and facilitate the implementation
of personalized care for overweight breast cancer patients, which should be considered as an unique
patient population.
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